menu
Influenza Therapeutics Market Size, Trends, Shares, Insights and Forecast – 2018-2026
Influenza Therapeutics Market Size, Trends, Shares, Insights and Forecast – 2018-2026
“Coherent Market Insights “INFLUENZA THERAPEUTICS MARKET – GLOBAL TRENDS, ESTIMATES AND FORECASTS, 2020-2027?

Increasing number of clinicalpipeline studies is expected to boost the InfluenzaTherapeutics Market growth during the forecast period. For instance, inJanuary 2018, Romark Laboratories L.C. initiated the phase 3 clinical trial forNitazoxanide to evaluate its efficacy and safety in the treatment ofuncomplicated influenza. Nitazoxanide is a broad-spectrum antiparasitic andbroad-spectrum antiviral drug, used in the treatment of intestinal parasiticinfections caused by Cryptosporidium parvam and Giardia lamblia. This study isexpected to be completed in April 2019.

Influenza is a condition thatcauses contagious illness. It is characterized by sudden onset of fever,headache, sore throat, non-productive cough, and rhinitis. Usually infectionlasts for about a week. Over the course of a flu season, different types andsubtypes of influenza can cause illness in humans. There are four types ofinfluenza virus such as A, B, C, and D. Influenza A and B virus causes most ofthe illness in humans. Prolonged influenza infections can cause severecomplications such as pneumonia, bronchitis, acute respiratory distress,secondary bacterial infections, and cardiovascular complications. To controlthe illness caused by influenza virus, influenza antiviral prescription drugscan be used.

Influenza Therapeutics Market:Drivers

New drug approvals for thetreatment of influenza is expected to drive the influenza therapeutics marketgrowth. For instance, in October 2018, Roche announced that the U.S. Food andDrug Administration (FDA) approved Xofluza (TM) (baloxavir marboxil) for thetreatment of acute, uncomplicated influenza or flu, in people 12 years of ageand older.

* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2443

Moreover, in November 2018, HenryM. Jackson Foundation for the Advancement of Military Medicine, initiated phase4 clinical trial study for egg-based influenza vaccines to study the realisticevaluation of influenza vaccine effectiveness in active duty members, militaryretirees, and other Department of Defense (DOD) beneficiaries.

Furthermore, rising initiativesby various sponsors to conduct phase 1 clinical trial to study the safetyparameter of anti-influenza drugs is expected to drive the market growth. Forinstance, in October 2018, Emory University started phase 1 clinical trial forseasonal influenza vaccine. The study has been designed to evaluate the impactof imprinting and repeated influenza vaccination on adaptive immunity,transcriptomics, and metabolomics. The study is expected to be completed inJuly 2020.

Influenza Therapeutics Market:Restraints

Influenza vaccines have severallimitations including relatively long production times, limited vaccinecapacity, moderate efficacy in certain people, and lack of cross-reactivity,which is projected to restrain growth of the influenza therapeutic marketduring the forecast period. Moreover, increasing concerns among people aboutthe side effects of vaccines hamper growth of the influenza therapeutic market.For instance, in October 2018, according to the National Opinion ResearchCentre (NORC) at the University of Chicago survey, around 43% of the adultswere vaccinated and 14% plans to receive the flu shot. However, around 41% ofthe American people reported that they are not vaccinated and do not intend toget vaccinated, as adults were most likely to cite concerns about side effectsof the vaccine.

Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/influenza-therapeutics-market-2443

Influenza Therapeutics Market:Regional Analysis

On the basis of region, theglobal influenza therapeutics market is segmented into North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa.

Asia Pacific is also expected towitness significant growth in the influenza therapeutics market, owing toincreasing initiatives by the Asia-Pacific Alliance for the Control ofInfluenza (APACI), to reduce the burden of influenza by enhancing controlmeasures and boosting pandemic preparedness in the region, through the provisionof educational information and activities.

Europe have also gainedsignificant position in the market, owing to increasing initiatives by EuropeanMedical Association (EMA) during an influenza pandemic season leading to  continuous monitoring of safety of centrallyauthorized pandemic influenza vaccines and antiviral medicines, and fast-trackreview of data for the authorization of pandemic influenza vaccines for use inall EU Member States. Also, increasing number of public awareness programs forthe prevention and diagnosis of influenza resulted in significant growth of theinfluenza therapeutics market in this region.

Key players operating in theglobal influenza therapeutic market include Daiichi Sankyo Company,GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., TevaPharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), SunPharmaceutical Industries Ltd., BiondVax Pharmaceuticals Ltd., AtrivaTherapeutics Gmbh, Texas Medical Center, Life Science Austria (LISA), GE HealthcareLife Sciences, Sanofi Pasteur SA and Mylan, Inc.

Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2443

AboutCoherent Market Insights:            

CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.

ContactUs:

mailto:sales@coherentmarketinsights.com

U.S.Office:

Name:  Mr. Shah

CoherentMarket Insights 1001 4th Ave,

# 3200Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN:  +050-5539-1737